Long-term follow-up confirms the favourable prognostic impact of high numbers of tumour infiltrating CD3 T-cells in follicular lymphoma patients treated by rituximab-maintenance regimen.
作者信息
Laurent Camille, Flores Maria, Chartier Loïc, Huet Sarah, Bolen Christopher R, Venstrom Jeffrey M, Chassagne-Clément Catherine, Dartigues-Cuilléres Peggy, Charlotte Fréderic, Tesson Bruno, Salles Gilles, Morschhauser Franck, Xerri Luc
机构信息
Institut Universitaire Cancer-Oncopole, CHU Toulouse, INSERM U1037, Toulouse, France.
LYSARC, Pierre Bénite, France.
出版信息
Br J Haematol. 2023 Aug;202(3):686-689. doi: 10.1111/bjh.18881. Epub 2023 May 22.
Abstract
摘要
相似文献
1
Long-term follow-up confirms the favourable prognostic impact of high numbers of tumour infiltrating CD3 T-cells in follicular lymphoma patients treated by rituximab-maintenance regimen.长期随访证实，在接受利妥昔单抗维持治疗方案的滤泡性淋巴瘤患者中，大量肿瘤浸润性CD3 T细胞具有良好的预后影响。
Br J Haematol. 2023 Aug;202(3):686-689. doi: 10.1111/bjh.18881. Epub 2023 May 22.
2
Low number of intrafollicular T cells may predict favourable response to rituximab-based immuno-chemotherapy in advanced follicular lymphoma: a secondary analysis of a randomized clinical trial.滤泡内 T 细胞数量低可能预示着对基于利妥昔单抗的免疫化疗治疗晚期滤泡性淋巴瘤的有利反应：一项随机临床试验的二次分析。
J Cancer Res Clin Oncol. 2019 Aug;145(8):2149-2156. doi: 10.1007/s00432-019-02961-9. Epub 2019 Jul 4.
3
Rituximab treatment circumvents the prognostic impact of tumor-infiltrating T-cells in follicular lymphoma patients.利妥昔单抗治疗可规避滤泡性淋巴瘤患者中肿瘤浸润性T细胞的预后影响。
Hum Pathol. 2017 Jun;64:128-136. doi: 10.1016/j.humpath.2017.03.023. Epub 2017 Apr 13.
4
Absolute B cell counts in blood predict long-term response in follicular lymphoma patients treated with rituximab without chemotherapy.血液中的绝对 B 细胞计数可预测未经化疗而接受利妥昔单抗治疗的滤泡性淋巴瘤患者的长期反应。
Ann Hematol. 2020 Oct;99(10):2357-2366. doi: 10.1007/s00277-020-04208-x. Epub 2020 Aug 17.
5
Long-term follow up of the FL2000 study comparing CHVP-interferon to CHVP-interferon plus rituximab in follicular lymphoma.FL2000 研究的长期随访结果：比较 CHVP-干扰素与 CHVP-干扰素联合利妥昔单抗治疗滤泡性淋巴瘤。
Haematologica. 2013 Jul;98(7):1107-14. doi: 10.3324/haematol.2012.082412. Epub 2013 May 3.
6
The tumour microenvironment influences survival and time to transformation in follicular lymphoma in the rituximab era.在利妥昔单抗时代，肿瘤微环境影响滤泡性淋巴瘤的生存及转化时间。
Br J Haematol. 2016 Oct;175(1):102-14. doi: 10.1111/bjh.14201. Epub 2016 Jun 24.
7
The incidence of biopsy-proven transformation in follicular lymphoma in the rituximab era. A retrospective analysis from the Czech Lymphoma Study Group (CLSG) database.利妥昔单抗时代滤泡性淋巴瘤经活检证实的转化发生率。来自捷克淋巴瘤研究组（CLSG）数据库的回顾性分析。
Ann Hematol. 2018 Apr;97(4):669-678. doi: 10.1007/s00277-017-3218-0. Epub 2018 Jan 9.
8
A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts.基于基因表达谱的滤泡性淋巴瘤患者预后预测评分：三队列回顾性训练和验证分析。
Lancet Oncol. 2018 Apr;19(4):549-561. doi: 10.1016/S1470-2045(18)30102-5. Epub 2018 Feb 20.
9
[Prognostic Significance of Follicular Lymphoma International Prognostic Index 2 (FLIPI2) in Follicular Lymphoma Patients Treated with Rituximab Maintenance].利妥昔单抗维持治疗的滤泡性淋巴瘤患者中滤泡性淋巴瘤国际预后指数2（FLIPI2）的预后意义
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2017 Apr;25(2):426-430. doi: 10.7534/j.issn.1009-2137.2017.02.021.
10
Combination lenalidomide-rituximab immunotherapy activates anti-tumour immunity and induces tumour cell death by complementary mechanisms of action in follicular lymphoma.来那度胺-利妥昔单抗联合免疫疗法通过互补的作用机制激活滤泡性淋巴瘤的抗肿瘤免疫并诱导肿瘤细胞死亡。
Br J Haematol. 2019 Apr;185(2):240-253. doi: 10.1111/bjh.15797. Epub 2019 Feb 14.
引用本文的文献
1
Adjuvant rituximab and elevated intratumoural CD8 expression are associated with sustained disease control after radiotherapy in a randomised trial of systemic therapy in early-stage follicular lymphoma.在一项早期滤泡性淋巴瘤全身治疗的随机试验中，辅助性利妥昔单抗和肿瘤内CD8表达升高与放疗后疾病的持续控制相关。
EBioMedicine. 2024 Dec;110:105468. doi: 10.1016/j.ebiom.2024.105468. Epub 2024 Dec 3.
2
Molecular Biomarkers in Prediction of High-Grade Transformation and Outcome in Patients with Follicular Lymphoma: A Comprehensive Systemic Review.分子生物标志物在预测滤泡性淋巴瘤患者高级别转化和结局中的作用：一项全面的系统性综述。
Int J Mol Sci. 2024 Oct 17;25(20):11179. doi: 10.3390/ijms252011179.
3
A brisk peripheral T-cell reaction following rituximab treatment for follicular lymphoma.利妥昔单抗治疗滤泡性淋巴瘤后出现的活跃外周T细胞反应。
Ann Hematol. 2024 Dec;103(12):6035-6037. doi: 10.1007/s00277-024-05931-5. Epub 2024 Aug 10.
本文引用的文献
1
Decreased expression of T-cell-associated immune markers predicts poor prognosis in patients with follicular lymphoma.T 细胞相关免疫标志物表达降低预示滤泡性淋巴瘤患者预后不良。
Cancer Sci. 2022 Feb;113(2):660-673. doi: 10.1111/cas.15224. Epub 2021 Dec 5.
2
Immune infiltrate diversity confers a good prognosis in follicular lymphoma.免疫浸润多样性预示滤泡性淋巴瘤预后良好。
Cancer Immunol Immunother. 2021 Dec;70(12):3573-3585. doi: 10.1007/s00262-021-02945-0. Epub 2021 Apr 30.
3
Treatment dependence of prognostic gene expression signatures in de novo follicular lymphoma.初发性滤泡性淋巴瘤中预后基因表达特征的治疗依赖性
Blood. 2021 May 13;137(19):2704-2707. doi: 10.1182/blood.2020008119.
4
Progression of Disease Within 24 Months in Follicular Lymphoma Is Associated With Reduced Intratumoral Immune Infiltration.在 24 个月内滤泡性淋巴瘤的疾病进展与肿瘤内免疫浸润减少有关。
J Clin Oncol. 2019 Dec 1;37(34):3300-3309. doi: 10.1200/JCO.18.02365. Epub 2019 Aug 28.
5
Mutation load and an effector T-cell gene signature may distinguish immunologically distinct and clinically relevant lymphoma subsets.突变负荷和效应T细胞基因特征可能区分免疫上不同且临床相关的淋巴瘤亚群。
Blood Adv. 2017 Sep 27;1(22):1884-1890. doi: 10.1182/bloodadvances.2016000786. eCollection 2017 Oct 10.
6
Rituximab treatment circumvents the prognostic impact of tumor-infiltrating T-cells in follicular lymphoma patients.利妥昔单抗治疗可规避滤泡性淋巴瘤患者中肿瘤浸润性T细胞的预后影响。
Hum Pathol. 2017 Jun;64:128-136. doi: 10.1016/j.humpath.2017.03.023. Epub 2017 Apr 13.
7
Automated prognostic pattern detection shows favourable diffuse pattern of FOXP3(+) Tregs in follicular lymphoma.自动预后模式检测显示滤泡性淋巴瘤中FOXP3(+)调节性T细胞呈良好的弥漫性模式。
Br J Cancer. 2015 Oct 20;113(8):1197-205. doi: 10.1038/bjc.2015.291. Epub 2015 Oct 6.
8
Pattern of CD14+ follicular dendritic cells and PD1+ T cells independently predicts time to transformation in follicular lymphoma.CD14+滤泡树突状细胞和PD1+ T细胞的模式可独立预测滤泡性淋巴瘤的转化时间。
Clin Cancer Res. 2014 Jun 1;20(11):2862-72. doi: 10.1158/1078-0432.CCR-13-2367. Epub 2014 Apr 11.
9
The reliability of immunohistochemical analysis of the tumor microenvironment in follicular lymphoma: a validation study from the Lunenburg Lymphoma Biomarker Consortium.滤泡性淋巴瘤肿瘤微环境免疫组化分析的可靠性：吕嫩堡淋巴瘤生物标志物联盟的一项验证研究
Haematologica. 2014 Apr;99(4):715-25. doi: 10.3324/haematol.2013.095257. Epub 2014 Feb 7.
10
Distribution, function, and prognostic value of cytotoxic T lymphocytes in follicular lymphoma: a 3-D tissue-imaging study.滤泡性淋巴瘤中细胞毒性 T 淋巴细胞的分布、功能和预后价值：一项 3D 组织成像研究。
Blood. 2011 Nov 17;118(20):5371-9. doi: 10.1182/blood-2011-04-345777. Epub 2011 Aug 19.
Zotero 插件